Genelabs submits Prestara protocol
This article was originally published in Pharmaceutical Approvals Monthly
Genelabs submits protocol for Phase III trial of its lupus therapy Prestara, with intent of confirming prasterone's positive effect on bone mineral density. FDA requested the trial in Aug. 28 "approvable" letter (Pharmaceutical Approvals Monthly, September 2002, In Brief). Genelabs hopes to begin the 110-patient, six-month trial before the end of the year. The trial will use bone mineral density at the lumbar spine as primary endpoin
You may also be interested in...
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Executive orders signed by Joe Biden in the first days of his presidency to support the US pandemic response – including calling for a plan to bolster domestic manufacturing capabilities – have received a warm welcome from the AAM.
Viartris hopes its Viagra Connect two-pack will encourage British men to seek treatment for erectile dysfunction.